Long-acting injectable CAB/RPV_SUPLA W24

Published: 22 January 2026| Version 2 | DOI: 10.17632/sd5c2366x9.2
Contributor:
Nan-Yu Chen

Description

Data from the SUPLA trial up to Week 24, with extended follow-up data available for a subset of participants. This dataset includes the following components: Study group assignment for each participant (gric) Longitudinal CD4 cell counts (cd4) and HIV-1 RNA levels (vir) collected during the trial Baseline resistance-associated mutations (resi) Depression (depr) and HIV self-stigma (stig) scores HIV diagnosis date, most recent HIV-1 RNA level, and CD4 count collected during eligibility screening (diag) Participant demographic and baseline clinical characteristics, including age, sex at birth, height, weight, and underlying comorbidities (dm) A list of participants excluded after randomization and the corresponding reasons for exclusion (OFF) Important note: Due to limitations of the electronic record system used in this study, the variable “visit” represents the page number of the electronic case report form rather than the actual visit number. Specifically, “Visit 2” corresponds to “Page 2” and contains the Day 1 records.

Files

Institutions

Categories

Human Immunodeficiency Virus Disease Treatment, Clinical Trial Results, Therapeutic Management in Adherence

Funders

Licence